Peter A. Pinto, MD

Peter A. Pinto, MD

U.S. National Institutes of Health

Bethesda, MD

Peter A. Pinto, MD, is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute in Bethesda, Maryland. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Pinto is a board-certified urologic surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

Disclosures:

Talks by Peter A. Pinto, MD

Image-Based Detection and Staging of Prostate Cancer: Is the TRUS Probe Facing Extinction?

Image-Based Detection and Staging of Prostate Cancer: Is the TRUS Probe Facing Extinction?

Posted by | Jul 2024

Peter A. Pinto, MD, explores the possibility of current imaging technology replacing the Transrectal Ultrasound (TRUS) probe in prostate cancer detection and staging. He begins with an overview of the weaknesses of the TRUS probe compared to magnetic resonance imaging (MRI) and MR/ultrasound fusion-guided biopsies in detecting and locating prostate cancer.

However, Dr. Pinto presents a comparison of the detection rates of TRUS-only biopsies with those of MR/ultrasound fusion-guided biopsies. He notes that both of these biopsy approaches can fail to detect low-risk and high-risk prostate cancers, leading to prostate cancer upgrading events.

Dr. Pinto concludes with an examination of the results from MRI-TRUS fusion biopsies. He presents the improved detection and certainty rates of the combined biopsy approach.

Read More
Fusion Biopsy Technologies and Techniques

Fusion Biopsy Technologies and Techniques

Posted by | Apr 2024

Peter A. Pinto, MD, discusses the evolution of prostate cancer biopsy and imaging techniques in the past twenty years, from blind systematic biopsies to MRI-ultrasound fusion biopsies. He begins by noting that prostate cancer was the only solid-organ tumor diagnosed without image guidance going into the 21st century.

When MRI was introduced as an imaging modality for prostate cancer diagnosis, urologists developed several different techniques for incorporating MRI into biopsy procedures. Dr. Pinto briefly covers the history and development of in-bore biopsies, cognitive fusion biopsies, and MRI-ultrasound fusion biopsies.

He concludes with reviewing the currently available devices in this space. He evaluates each system as it relates to biopsy needle targeting route, tracking and navigation, MRI-ultrasound fusion opportunities, ultrasound image acquisition, and biopsy fixation.

Read More
Biomarkers Made Simple

Biomarkers Made Simple

Posted by | Mar 2024

Peter A. Pinto, MD, presents an overview of the roles of biomarkers in prostate cancer diagnosis and screening. In his presentation, Dr. Pinto covers:

Biomarkers Categorization
Tissue-Based Biomarkers
Emerging Urine-Based Biomarkers
Biomarker Detection
Challenges and Opportunities in Biomarker Research

Read More
Focal and Salvage Therapies for Prostate Cancer: What’s Worth It and What’s Not?

Focal and Salvage Therapies for Prostate Cancer: What’s Worth It and What’s Not?

Posted by | Jan 2024

Peter A. Pinto, MD, examines the current state of focal and salvage therapies for the treatment of prostate cancer, and offers his insights into which therapies are worth pursuing. He begins by addressing various kinds of salvage therapy, acknowledging that salvage therapy is a response to failed focal, radiation, or surgical therapy, and specifying that this presentation will focus on salvage therapy after failed radiation therapy.

Dr. Pinto explains that focal ablation therapy, whole gland ablation therapy, and surgical therapy are the most common salvage therapies after a radiation therapy failure. He recommends using an MRI-based biopsy method over more traditional methods to maximize accuracy in identifying lesions.

Dr. Pinto then recommends focal ablation over whole gland ablation as a salvage therapy after failed radiation therapy due to the high morbidity associated with whole gland ablation. Dr. Pinto concludes by listing the many ablation options for salvage therapy, and presents studies which examined the pros and cons of each option, offering his insights on each study.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -